Skip to main content

Post-IPO Equity Biotechnology Companies

Explore 483 biotechnology startups that raised post-ipo equity funding. Access verified founder contact information and fundraising data.

Total Companies
483
Total Funding
$2.5B
Avg Funding
$100.9M
Cities
25

Export 483 Post-IPO Equity Biotechnology Companies

Get founder emails, funding data, and company details in one CSV

Start Free Trial

Recently Funded Companies

Export
Victoria, Canada
$63.2M
raised

Eupraxia is a clinical-stage biotech company developing locally delivered, extended-release alternatives to currently approved drugs.

Feb 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Morristown, United States
$12.0M
raised

Cingulate Therapeutics uses a unique combination of delivery technology and proven medications that creates an unmatched release profile.

Feb 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

New York, United States
$400.0M
raised

Immunic is a biopharmaceutical company that develops a pipeline of selective oral immunology therapies.

Feb 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Palo Alto, United States
$125.0M
raised

Evommune is a biotechnology company that develops therapeutics that halt progressive disease and address their symptoms.

Feb 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Redwood City, United States
$50.1M
raised

Coherus Biosciences develops, manufactures, and commercializes biologic therapeutics for oncology and inflammatory diseases.

Feb 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Ready to Reach These Founders?

Get verified contact info for decision-makers at 483 funded startups

41,000+ verified emails
Unlimited exports
No credit card required
Waltham, United States
$40.0M
raised

Xilio Therapeutics is a biotechnology company that develops tumor-activated immuno-oncology therapies.

Feb 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Copenhagen, Denmark
$275.0M
raised

Galecto is a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer.

Feb 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Coolum Beach, Australia
$4.9M
raised

Terragen offers natural and sustainable solutions for farming by creating products that improve health and condition of animals and plants.

Feb 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Saint Laurent, Canada
$4.6M
raised

Cannara Biotech is to operate the largest indoor medical cannabis cultivation facility.

Feb 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Houston, United States
$11.1M
raised

Coya Therapeutics is a T Reg platform company addressing neurodegenerative, autoimmune, and metabolic diseases

Jan 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Ready to Reach These Founders?

Get verified contact info for decision-makers at 483 funded startups

41,000+ verified emails
Unlimited exports
No credit card required
Singapore, Singapore
$91.1M
raised

Mirxes is an RNA technology company that develops blood-based miRNA test kits for early disease detection.

Jan 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Menlo Park, United States
$11.2M
raised

Revelation Biosciences develops immunologic therapeutics and diagnostics designed to make the world a healthier place.

Jan 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Calgary, Canada
$886K
raised

Onco-Innovations is a biotech business that develops and commercializes medicines for various cancers.

Jan 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Richmond, United States
$115.0M
raised

BioAge Labs is a clinical-stage biotechnology company that develops therapeutics to treat obesity and metabolic diseases.

Jan 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Burlingame, United States
$201.0M
raised

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company.

Jan 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Ready to Reach These Founders?

Get verified contact info for decision-makers at 483 funded startups

41,000+ verified emails
Unlimited exports
No credit card required
Chester, United Kingdom
$55.0M
raised

Canton Strategic Holdings drives institutional blockchain adoption via the Canton Network, digital assets, and market digitization.

Jan 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Boston, United States
$9.3M
raised

MetaVia is a clinical-stage biotechnology company that develops and commercializes multimodal disease-modifying therapies.

Jan 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Garden City, United States
$5.0M
raised

Beyond Air is a biotechnology company that focuses on the development of drugs for the treatment of lung infections.

Jan 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Alpharetta, United States
$12.5M
raised

Dogwood Therapeutics is a clinical-stage biopharmaceutical company developing novel antiviral therapies for fibromyalgia and other diseases.

Jan 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Los Angeles, United States
$75.0M
raised

Kairos Pharma is a clinical-stage biopharmaceutical company focused on cancer immunotherapy and drug resistance.

Jan 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Ready to Reach These Founders?

Get verified contact info for decision-makers at 483 funded startups

41,000+ verified emails
Unlimited exports
No credit card required
Cambridge, United States
$50.0M
raised

Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express,

Jan 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Philadelphia, United States
$135.0M
raised

Century Therapeutics is a biotechnology company that develops cell therapies for hematological and solid tumor malignancies.

Jan 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Basel, Switzerland
$300.0M
raised

Monte Rosa Therapeutics is a biotechnology company that develops cancer therapeutics that modulate protein degradation pathways.

Jan 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

San Francisco, United States
$345.1M
raised

Alumis is a precision medicine company focused on the discovery, development and treatment of autoimmune disorders.

Jan 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Florham Park, United States
$130.0M
raised

Phathom Pharmaceuticals is a biopharmaceutical company.

Jan 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Showing 176 to 200 of 483 companies

Ready to Connect with Post-IPO Equity Biotechnology Startups?

Get verified founder emails, funding details, and company data for 483 post-ipo equity biotechnology companies.

Get Started - Access Contact Information

Join thousands of sales teams, investors, and service providers using VCBacked

483 Biotechnology Post-IPO Equity Startups (November 2026) — Page 8 | VCBacked